KIYATEC, LLC
Patient-specific cancer treatment response prediction platform using tumor biomarkers and molecular profiling
- Sector
- Biotech
- Headquarters
- GREENVILLE, SC
- Latest Form D
- $250K, Nov 2024
- Total capital
- $29.4M
- Federal grants
- $5.5M
- 7 awards · 2015–2018
- Rank in peer group#8 of 13
- Private capital raised
- $23.8M
- 8 Form D · last Nov 2024
- 24 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 1 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 8th filing$250K
- Private capital raisedForm D · SEC · 7th filing$18.1M
- Private capital raisedForm D · SEC · 6th filing$5.3M
- Federal grantHealth and Human S · Phase II · he 3D Platelet Bank: A Clinical-grade, Scalable, 3D Microbioreactor Bone Marrow Mimetic for Platelet Production$827K
- Offering registeredForm D · SEC · 5th filing$2M
- Federal grantHealth and Human S · Phase II · he 3D Platelet Bank: A Clinical-grade, Scalable, 3D Microbioreactor Bone Marrow Mimetic for Platelet Production$1.8M
- Federal grantHealth and Human S · Phase II · he 3D Platelet Bank: A Clinical-grade, Scalable, 3D Microbioreactor Bone Marrow Mimetic for Platelet Production$937K
- Offering registeredForm D · SEC · 4th filing$3.1M
- Private capital raisedForm D · SEC · 3rd filing$180K
- Offering registeredForm D · SEC · 2nd filing$501K
- Offering registeredForm D · SEC · 1st filing$2.8M
Show 3 earlier federal awards
- Federal grantHealth and Human S · Phase I · The 3D Platelet Bank: A Clinical-grade, Scalable, 3D Microbioreactor Bone Marrow Mimetic for Platelet Production$29K
- Federal grantHealth and Human S · Phase I · The 3D Platelet Bank: A Clinical-grade, Scalable, 3D Microbioreactor Bone Marrow Mimetic for Platelet Production$225K
- Federal grantHealth and Human S · Phase I · The 3D Platelet Bank: A Clinical-grade, Scalable, 3D Microbioreactor Bone Marrow Mimetic for Platelet Production$254K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Standing among 13 peers
Line = medianBiotech · System
- Federal grantsBelow median
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Bob Lee SilvermanDirectorNamed in SEC Form D filings
- Bruce NashDirectorNamed in SEC Form D filings
- Christine R. Dixon ThiesingDirectorNamed in SEC Form D filings
- Christine Dixon ThiesingDirectorNamed in SEC Form D filings
- Christopher BrothertonDirectorNamed in SEC Form D filings
- David E OrrExecutive OfficerNamed in SEC Form D filings
Show all 15 people
- Eric PerreaultExecutive Officer, DirectorNamed in SEC Form D filings
- Gregory ZaicDirectorNamed in SEC Form D filings
- H. Lee Higdon IIIDirectorNamed in SEC Form D filings
- Jason RobartDirectorNamed in SEC Form D filings
- Martin EttlemyerDirectorNamed in SEC Form D filings
- Matthew GevaertExecutive Officer, DirectorNamed in SEC Form D filings
- Melissa RaynerExecutive OfficerNamed in SEC Form D filings
- Robert SilvermanDirectorNamed in SEC Form D filings
- Scott IsacksenExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 1- PendingBioreactor SystemUSPTOApplication PCTUS2010039119
Related companies, and why
- COLLABORATIONS PHARMACEUTICALS INCSimilar federal contract value in Biotech · null in contracts
- Novan, Inc.Similar federal contract value in Biotech · null in contracts
- AXONIS THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Mitokinin, Inc.Similar federal contract value in Biotech · null in contracts
- Suono Bio Inc.Similar federal contract value in Biotech · null in contracts
- EnBiotix, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .